All Afferent articles
-
Business
Merck & Co to buy Afferent for neurology drugs
Deal worth up to $1.25bn includes drug candidate for chronic coughs
2016-06-13T00:00:00Z
Deal worth up to $1.25bn includes drug candidate for chronic coughs
Site powered by Webvision Cloud